Background New prevention strategies for respiratory syncytial virus (RSV) are emerging,
but it is unclear if they will be cost-effective in low-and middle-income countries. We …

Objectives Interventions to prevent childhood respiratory syncytial virus (RSV) disease are
limited and costly. New interventions are in advanced stages of development and could be …

Background Respiratory syncytial virus (RSV) is a leading cause of respiratory disease in
young children. A number of mathematical models have been used to assess the cost …

Background Respiratory syncytial virus (RSV) frequently causes acute lower respiratory
infection in children under 5, representing a high burden in Gavi-eligible countries (mostly …

Importance Low-and middle-income countries have a high burden of respiratory syncytial
virus lower respiratory tract infections. A monoclonal antibody administered monthly is …

Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV)
are in development and likely to be available in the next 5–10 years. The most efficient way …

Respiratory syncytial virus (RSV) is the most common cause of early childhood lower
respiratory tract infection (LRTI) in low-and middle-income countries (LMICs). Maternal …

Background Every winter, respiratory syncytial virus (RSV) disease results in thousands of
cases in Norwegian children under 5 years of age. We aim to assess the RSV-related …

Background The cost-effectiveness of immunisation strategies with a long-acting
monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for …

Background Passive immunization against RSV (Respiratory Syncytial Virus) is given in
most western countries (including Israel) to infants of high risk groups such as premature …